What is the recommended treatment for autoimmune hepatitis in flare or liver failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 22, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Autoimmune Hepatitis in Flare or Liver Failure

For AIH flare without liver failure, immediately initiate high-dose prednisone 30 mg daily combined with azathioprine 50 mg daily (or 1-2 mg/kg/day), tapering prednisone to 10 mg daily over 4 weeks while maintaining azathioprine; for patients with liver failure or severe decompensation, start high-dose prednisone 60 mg daily (or 30 mg daily with azathioprine 150 mg daily) and simultaneously contact a liver transplant center. 1

Immediate Assessment and Risk Stratification

Determine severity within 2 weeks of presentation to guide management decisions. Look specifically for:

  • Bilirubin levels and trajectory: Hyperbilirubinemia that fails to improve after 2 weeks of treatment predicts need for urgent transplantation 1, 2
  • MELD score: If ≥15 or not rapidly improving on treatment, immediate transplant center contact is mandatory 1, 2
  • Hepatic encephalopathy: Development or worsening despite treatment indicates transplant evaluation 2
  • Multiacinar/bridging necrosis on biopsy: Predicts treatment failure and need for transplantation 1, 2
  • Ascites: Most common sign of decompensation requiring transplant consideration 1, 2

Treatment Protocol for AIH Flare (Without Liver Failure)

Standard Flare Management

Initiate combination therapy immediately with prednisone 30 mg daily plus azathioprine 50 mg daily (or 1-2 mg/kg/day). 1, 3, 4 This combination produces significantly fewer corticosteroid-related side effects than high-dose prednisone alone (10% versus 44%). 1, 3, 4

Taper prednisone over 4 weeks to 10 mg daily while maintaining azathioprine at the same dose. 1, 3, 4 The tapering schedule is:

  • Week 1: Prednisone 30 mg + Azathioprine 50 mg
  • Week 2: Prednisone 20 mg + Azathioprine 50 mg
  • Week 3: Prednisone 15 mg + Azathioprine 50 mg
  • Week 4 onward: Prednisone 10 mg + Azathioprine 50 mg 1

Delay azathioprine initiation if bilirubin >6 mg/dL (100 μmol/L); start azathioprine ideally 2 weeks after steroid initiation once bilirubin improves. 1, 4

Monitoring Response

Assess treatment response at 2 weeks: Serum aminotransferases should improve within 2 weeks of starting therapy. 3, 4, 2 Favorable indicators include:

  • Resolution of at least one laboratory abnormality
  • Improvement in hyperbilirubinemia
  • Failure of any test to worsen during treatment 1, 2

Monitor monthly thereafter: Small decrements in prednisone can cause marked increases in aminotransferases. 3 Continue treatment until complete normalization of transaminases AND IgG levels. 1, 3, 4

Treatment Protocol for Liver Failure or Severe Decompensation

High-Dose Corticosteroid Therapy

All decompensated patients warrant a corticosteroid trial before proceeding to transplantation, even those with advanced disease, ascites, or low-grade encephalopathy. 1, 2 Some will improve sufficiently to avoid immediate transplantation. 1, 2

Two high-dose regimens are endorsed by AASLD guidelines: 1, 2

  1. Prednisone 60 mg daily alone, OR
  2. Prednisone 30 mg daily + azathioprine 150 mg daily

Maintain high-dose therapy for at least 1 month, then reduce by 10 mg prednisone and 50 mg azathioprine monthly as clinical and laboratory findings improve, until reaching conventional maintenance doses (prednisone 10-20 mg daily, azathioprine 50 mg daily). 1

Critical Pitfall: Early Transplant Referral

Contact transplant center immediately if any of the following are present: 1, 2

  • Liver failure at presentation
  • MELD score >15
  • Bilirubin not improving after 2 weeks of treatment
  • Development or worsening of hepatic encephalopathy
  • Clinical decompensation (ascites, variceal bleeding, hepatorenal syndrome)

Do NOT delay referral waiting for treatment response in severely ill patients. The 2-week assessment window determines transplant urgency. 1, 2

Special Considerations for Children

Children with treatment failure (5-15% of cases) should receive the same high-dose regimens as adults and be considered for transplantation. 1, 2 However, recurrent AIH post-transplant is more frequent in children than adults and may be less responsive to treatment, resulting in graft loss. 1, 2

Alternative Agents for Refractory Cases

If standard high-dose therapy fails after 1 month, consider: 1

  • Tacrolimus (starting 0.075 mg/kg daily): May be more effective for refractory disease 4
  • Cyclosporine (2-5 mg/kg daily): Effective in some treatment failures 1, 4
  • Mycophenolate mofetil (1-2 g daily): First-line for azathioprine intolerance, but limited efficacy in true treatment failure 1, 4

Ursodeoxycholic acid and budesonide have been evaluated and shown negative results as salvage therapies. 1

Long-Term Management After Flare Resolution

Continue treatment for at least 2 years and for at least 12 months after complete normalization of transaminases and IgG. 1, 3, 4 Relapse occurs in 50-90% within 12 months of stopping treatment. 1, 3

After relapse, indefinite maintenance therapy is advisable: Use azathioprine 2 mg/kg daily alone or low-dose prednisone combinations, with 87% remaining in remission during median 67-month follow-up. 3, 5

Transplant Outcomes

Liver transplantation is highly successful in AIH with 5-year survival of 75-92% and 10-year survival of 75%. 1, 2 Recurrent AIH occurs in approximately 30% of adults post-transplant but is typically mild and manageable with prednisone and calcineurin inhibitor combinations. 1, 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Treatment of Severe Autoimmune Hepatitis Refractory to Medical Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Autoimmune Hepatitis Type 2

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Autoimmune Hepatitis Treatment Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.